DEALS: Isis, Alnylam form RNAi company

DEALS

WHO

WITH

WHAT

SCOOP

Alpharma

IDEA

$202 licensing deal

Alpharma has agreed to pay Germany's IDEA up to $202 million in upfront fees and milestones for the U.S. rights to the late-stage pain drug Diractin, a prescription topical NSAID.

Nabi Biopharmaceuticals

Biotest

$185M sale

Nabi Biopharmaceuticals plans to sell its biologics unit to Germany's Biotest for $185 million.

Boehringer Ingelheim

Ablynx

$103.5M partnership

Boehringer has signed a second agreement with Ablynx to develop and commercialize up to 10 different Nanobody therapeutics.

Medivation

Azimuth Opportunity

$100M stock deal

VC firm Azimuth Opportunity will purchase $100 million of Medivation's stock over the next 18 months as the drug developer pushes through a late-stage trial of an experimental Alzheimer's drug.

Meda

BioDelivery Sciences

$90M licensing deal

Meda will pay BioDelivery up to $90 million in exchange for a licensing deal covering the North American rights to BEMA Fentanyl, a new pain patch for cancer patients.

Ventana Medical Systems

Spring BioScience

$31M acquisition

Ventana Medical Systems has inked a deal to acquire Spring BioScience, which makes rabbit monoclonal antibodies and other reagents.

Isis Pharmaceuticals

Alnylam Pharmaceuticals

Company formation

Isis and Alnylam have teamed up to form Regulus Therapeutics, a company that will focus on developing new drugs based on micro-RNA.